Effect of progestogen on glycogen metabolism in the endometrium of infertile patients during the menstrual cycle. 1981

H Mimori, and K Fukuma, and I Matsuo, and K Nakahara, and M Maeyama

The glycogen content and glycogen synthetase and glycogen phosphorylase levels were studied in endometrial samples obtained from 19 normal and 37 infertile patients during the menstrual cycle before and after administration of progestogen. Each of the above groups received the progestogen Lyndiol (lynestrenol, 5.0 mg, and mestranol, 0.15 mg) daily for 7 days during the follicular phase of the menstrual cycle. In both groups an increase in the endometrial glycogen deposition and an increase in glycogen synthetase enzyme levels were seen. When the administration of progestogen was started on day 7 after ovulation, during the luteal phase, the glycogen content of endometrial tissue from infertile patients increased significantly; no change was found in endometrial samples from normal patients. No difference was found in the serum progesterone levels of normal and infertile patients in the midsecretory phase of menstrual cycle, and Lyndiol reduced the serum level of progesterone to approximately that found during the follicular phase in untreated normal women. These studies suggest that the proliferative endometrium of infertile patients may be less stimulated by ovarian estrogen than is normal endometrium, whereas endometrial tissue obtained from both groups during the luteal phase responded similarly to progesterone in glycogen synthesis and storage.

UI MeSH Term Description Entries
D007247 Infertility, Female Diminished or absent ability of a female to achieve conception. Sterility, Female,Sterility, Postpartum,Sub-Fertility, Female,Subfertility, Female,Female Infertility,Female Sterility,Female Sub-Fertility,Female Subfertility,Postpartum Sterility,Sub Fertility, Female
D008234 Lynestrenol A synthetic progestational hormone used often in mixtures with estrogens as an oral contraceptive (CONTRACEPTIVES, ORAL). 19-Norpregn-4-en-20-yn-17-ol, (17alpha)-,Ethinylestrenol,Exluton,Linesterol,Linestrenol,Lynestrenol, (9 beta, 10 alpha,17 alpha)-Isomer,Lynoestrenol
D008598 Menstruation The periodic shedding of the ENDOMETRIUM and associated menstrual bleeding in the MENSTRUAL CYCLE of humans and primates. Menstruation is due to the decline in circulating PROGESTERONE, and occurs at the late LUTEAL PHASE when LUTEOLYSIS of the CORPUS LUTEUM takes place.
D008656 Mestranol The 3-methyl ether of ETHINYL ESTRADIOL. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL CONTRACEPTIVES. 19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-methoxy-, (17alpha)-,Ethinyl Estradiol 3-Methyl Ether,Ethinyl Estradiol 3 Methyl Ether
D011372 Progestins Compounds that interact with PROGESTERONE RECEPTORS in target tissues to bring about the effects similar to those of PROGESTERONE. Primary actions of progestins, including natural and synthetic steroids, are on the UTERUS and the MAMMARY GLAND in preparation for and in maintenance of PREGNANCY. Gestagenic Agent,Progestagen,Progestagenic Agent,Progestational Agent,Progestational Compound,Progestational Hormone,Progestogen,Progestogens,Gestagen,Gestagen Effect,Gestagen Effects,Gestagenic Agents,Gestagenic Effect,Gestagenic Effects,Gestagens,Progestagenic Agents,Progestagens,Progestational Agents,Progestational Compounds,Progestational Hormones,Progestin,Progestin Effect,Progestin Effects,Progestogen Effect,Progestogen Effects,Agent, Gestagenic,Agent, Progestagenic,Agent, Progestational,Compound, Progestational,Effect, Gestagen,Effect, Gestagenic,Effect, Progestin,Effect, Progestogen,Effects, Gestagen,Effects, Gestagenic,Effects, Progestin,Effects, Progestogen,Hormone, Progestational
D003277 Contraceptives, Oral, Combined Fixed drug combinations administered orally for contraceptive purposes. Combined Oral Contraceptive,Contraceptive Agents, Female, Combined,Oral Contraceptives, Combined,Combined Oral Contraceptives,Contraceptive, Combined Oral,Contraceptives, Combined Oral,Oral Contraceptive, Combined
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004717 Endometrium The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo. Endometria
D005260 Female Females
D006003 Glycogen

Related Publications

H Mimori, and K Fukuma, and I Matsuo, and K Nakahara, and M Maeyama
April 1975, Arkhiv anatomii, gistologii i embriologii,
H Mimori, and K Fukuma, and I Matsuo, and K Nakahara, and M Maeyama
January 1975, Journal of steroid biochemistry,
H Mimori, and K Fukuma, and I Matsuo, and K Nakahara, and M Maeyama
December 1953, Endocrinology,
H Mimori, and K Fukuma, and I Matsuo, and K Nakahara, and M Maeyama
May 1968, Nihon Naibunpi Gakkai zasshi,
H Mimori, and K Fukuma, and I Matsuo, and K Nakahara, and M Maeyama
April 1995, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists,
H Mimori, and K Fukuma, and I Matsuo, and K Nakahara, and M Maeyama
May 2010, Molecular human reproduction,
H Mimori, and K Fukuma, and I Matsuo, and K Nakahara, and M Maeyama
October 1975, The Journal of clinical endocrinology and metabolism,
H Mimori, and K Fukuma, and I Matsuo, and K Nakahara, and M Maeyama
December 1972, American journal of obstetrics and gynecology,
H Mimori, and K Fukuma, and I Matsuo, and K Nakahara, and M Maeyama
October 1989, Nihon Sanka Fujinka Gakkai zasshi,
Copied contents to your clipboard!